106 related articles for article (PubMed ID: 12875291)
1. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection.
Flanagan KL; Mwangi T; Plebanski M; Odhiambo K; Ross A; Sheu E; Kortok M; Lowe B; Marsh K; Hill AV
Am J Trop Med Hyg; 2003 Apr; 68(4):421-30. PubMed ID: 12875291
[TBL] [Abstract][Full Text] [Related]
2. Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation.
Flanagan KL; Plebanski M; Odhiambo K; Sheu E; Mwangi T; Gelder C; Hart K; Kortok M; Lowe B; Robson KJ; Marsh K; Hill AV
Am J Trop Med Hyg; 2006 Mar; 74(3):367-75. PubMed ID: 16525093
[TBL] [Abstract][Full Text] [Related]
3. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area.
Moormann AM; John CC; Sumba PO; Tisch D; Embury P; Kazura JW
Am J Trop Med Hyg; 2006 Apr; 74(4):585-90. PubMed ID: 16606988
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium falciparum liver-stage antigen-1 peptide-specific interferon-gamma responses are not suppressed during uncomplicated malaria in African children.
Luty AJ; Bongartz M; Rezbach P; Faucher JF; Hollingdale MR; Kremsner PG
Eur Cytokine Netw; 2001; 12(4):647-53. PubMed ID: 11781192
[TBL] [Abstract][Full Text] [Related]
5. HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls.
Lyke KE; Burges RB; Cissoko Y; Sangare L; Kone A; Dao M; Diarra I; Fernández-Vina MA; Plowe CV; Doumbo OK; Sztein MB
Infect Immun; 2005 Sep; 73(9):5799-808. PubMed ID: 16113298
[TBL] [Abstract][Full Text] [Related]
6. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease.
Reece WH; Pinder M; Gothard PK; Milligan P; Bojang K; Doherty T; Plebanski M; Akinwunmi P; Everaere S; Watkins KR; Voss G; Tornieporth N; Alloueche A; Greenwood BM; Kester KE; McAdam KP; Cohen J; Hill AV
Nat Med; 2004 Apr; 10(4):406-10. PubMed ID: 15034567
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cellular and humoral responses to recombinant protein and synthetic peptides of exon2 region of Plasmodium falciparum erythrocyte membrane protein1 (PfEMP1) among malaria patients from an endemic region.
Das P; Grewal JS; Mahajan B; Chauhan VS
Parasitol Int; 2007 Mar; 56(1):51-9. PubMed ID: 17258500
[TBL] [Abstract][Full Text] [Related]
8. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
[TBL] [Abstract][Full Text] [Related]
9. Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children.
D'Ombrain MC; Robinson LJ; Stanisic DI; Taraika J; Bernard N; Michon P; Mueller I; Schofield L
Clin Infect Dis; 2008 Dec; 47(11):1380-7. PubMed ID: 18947328
[TBL] [Abstract][Full Text] [Related]
10. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
[TBL] [Abstract][Full Text] [Related]
11. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.
Meraldi V; Romero JF; Kensil C; Corradin G
Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728
[TBL] [Abstract][Full Text] [Related]
12. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.
Polley SD; Mwangi T; Kocken CH; Thomas AW; Dutta S; Lanar DE; Remarque E; Ross A; Williams TN; Mwambingu G; Lowe B; Conway DJ; Marsh K
Vaccine; 2004 Dec; 23(5):718-28. PubMed ID: 15542195
[TBL] [Abstract][Full Text] [Related]
13. Differential T-cell responses of semi-immune and susceptible malaria subjects to in silico predicted and synthetic peptides of Plasmodium falciparum.
Dinga JN; Kimbung Mbandi S; Cho-Ngwa F; Fon NP; Moliki J; Efeti RM; Nyasa BR; Anong DN; Jojic N; Heckerman D; Wang R; Titanji VP
Acta Trop; 2014 Jul; 135():104-21. PubMed ID: 24681218
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin related adhesive protein (TRAP), a potential malaria vaccine candidate.
Dolo A; Modiano D; Doumbo O; Bosman A; Sidibé T; Keita MM; Naitza S; Robson KJ; Crisanti A
Parassitologia; 1999 Sep; 41(1-3):425-8. PubMed ID: 10697897
[TBL] [Abstract][Full Text] [Related]
15. Malaria antigen-mediated enhancement of interleukin-21 responses of peripheral blood mononuclear cells in African adults.
Mewono L; Agnandji ST; Matondo Maya DW; Mouima AM; Iroungou BA; Issifou S; Kremsner PG
Exp Parasitol; 2009 May; 122(1):37-40. PubMed ID: 19545527
[TBL] [Abstract][Full Text] [Related]
16. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria.
John CC; Moormann AM; Sumba PO; Ofulla AV; Pregibon DC; Kazura JW
Infect Immun; 2004 Sep; 72(9):5135-42. PubMed ID: 15322007
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
[TBL] [Abstract][Full Text] [Related]
19. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A24 restricted pre-erythrocytic stage specific T-cell epitopes using Plasmodium falciparum synthetic peptides: a preliminary study.
Tippawangkosol P; Duangchanda T; Ubalee R; Ruengweerayut R; Hirayama K; Na-Bangchang K
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):10-7. PubMed ID: 19323028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
